drugset

drugset / Trial / NCT00981682

Long Term Safety Assessment of SER120 in Patients With Nocturia

NCT00981682 ↗

Phase 3 Completed 376 enrolled Serenity Pharmaceuticals, Inc.

NaSingle-groupOpen-labelTreatment

Summary

The hypothesis of this study is that SER120 is safe and well tolerated for use in nocturic patients.

Timeline

Start: 2009-08
Primary completion: 2011-06
Completion: 2011-08

Drugs

Evaluation	Drug	Modality	Dose	Route
Subject	Desmopressin	Peptide	—	Intranasal

Indications